| Literature DB >> 2895829 |
I MacIntyre1, J C Stevenson, M I Whitehead, S J Wimalawansa, L M Banks, M J Healy.
Abstract
A 2-year randomised pilot study was conducted in 70 patients to see whether the osteoclast-inhibiting effect of calcitonin would reduce postmenopausal vertebral bone loss. An oestradiol-treated group was included in the study as a positive control since oestrogens are known to be effective. Calcitonin reduced vertebral bone loss in doses above 250 micrograms human calcitonin (50 international units) a week, and at this dose was as effective as oestradiol.Entities:
Mesh：
Substances：
Year: 1988 PMID： 2895829 DOI： 10.1016/s0140-6736(88)91712-6
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321